Modufolin
- Generic Name
- Modufolin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O6
- CAS Number
- 31690-11-6
- Unique Ingredient Identifier
- Z8R4A37V9Q
- Background
Modufolin is under investigation for the treatment of Osteosarcoma.
Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape
• DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.
• Key drug candidates include XL092 (Exelixis), Adagrasib (Mirati Therapeutics), Olaparib (Merck/AstraZeneca), and novel approaches like LYL845, an autologous tumor-infiltrating lymphocyte therapy from Lyell Immunopharma.
• The metastatic colorectal cancer segment shows particular promise with 150+ companies advancing 180+ pipeline therapies, including innovative treatments targeting specific mutations and immune pathways.
Isofol Medical Advances Arfolitixorin Development with New Phase Ib/II Trial for Metastatic Colorectal Cancer
• Isofol Medical has received regulatory approval to initiate a Phase Ib/II clinical trial evaluating arfolitixorin in first-line treatment of metastatic colorectal cancer at Germany's prestigious Charité Universitätsmedizin Berlin.
• The new study implements an optimized dosing regimen with higher doses administered earlier in the treatment cycle, designed to enhance arfolitixorin's synergistic effects with 5-FU chemotherapy.
• The trial will replace leucovorin with arfolitixorin in standard treatment protocols and will be conducted in two stages: dose escalation assessment followed by efficacy comparison between selected dosages.
Arfolitixorin Shows Promise in Post-Hoc Analysis of Phase III AGENT Trial for Colorectal Cancer
A new post-hoc analysis of the Phase III AGENT study, presented at ASCO GI 2025, reveals favorable outcomes for arfolitixorin in colorectal cancer treatment, particularly in North America where it achieved an 85.7% objective response rate compared to 45.5% with leucovorin. The analysis suggests that protocol compliance and regional differences in treatment administration significantly impacted the study's outcomes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath